In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.

[EX Q]: Verifying Authority and Legality In Drug Compounding Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs.

Eliminates authority for compounding pharmacies to: (1) compound drugs before the receipt of a valid prescription order, or (2) compound any drug product that is a copy of a commercially available drug.

Requires the Secretary of Health and Human Services (HHS) to develop, maintain and transmit to the appropriate state agencies a list of drug products that should not be compounded, including: (1) drug products whose compounding is reasonably likely to cause an adverse effect on their safety or effectiveness; and (2) drug products that have been withdrawn or removed from the market because they have been found to be unsafe or not effective.

Authorizes the Secretary to waive the requirement that a drug product must be compounded for an individually identified patient based on a valid prescription order or similar notation if compounding the drug product is necessary to address a drug shortage, or to protect public health or well-being. Prohibits the Secretary from authorizing a state to grant such waivers.

Authorizes the Secretary to waive the requirement that a drug product must be compounded for an individually identified patient based on a valid prescription order or similar notation if the pharmacy or pharmacist: (1) submits a satisfactory application to the Secretary; and (2) agrees to comply with any condition or limitation specified by the Secretary. Makes a pharmacy or pharmacist required to be registered under the FFDCA as a drug producer ineligible for a waiver. Permits the Secretary to authorize a state to grant such waivers applicable to compounded drug products sold or dispensed within the state pursuant to a memorandum of understanding between the Secretary and the state.

Authorizes the Secretary to waive the prohibition against compounding any drug product that is a copy of a commercially available drug if it is necessary to protect public health or well-being. Prohibits the Secretary from authorizing a state to waive such prohibition.

Subjects the facilities of any pharmacy receiving a waiver under this Act to inspection to determine compliance with this Act.

Requires the Secretary to publish notice at least 30 days before cancelling a waiver, unless it is necessary to prevent an adverse impact on public health or safety.

Sets forth a required label statement for any drug compounded pursuant to this Act.

 Requires a pharmacist or physician compounding a drug product to report any adverse event associated with the use of the product within a specified time frame.
[EX A]: To amend the Federal Food, Drug, and Cosmetic Act to provide for the compounding of drug products.

[EX Q]: Smarter Approach to Nuclear Expenditures Act This bill prohibits the obligation or expenditure of Department of Defense (DOD) funds: (1) for procuring more than eight Columbia-class submarines; (2) to maintain more than 150 deployed intercontinental ballistic missiles; or (3) through FY2024, for the research, development, test, and evaluation (RDT&amp;E) or the procurement of the B-21 long-range penetrating bomber aircraft. The bill prohibits the obligation or expenditure of DOD or Department of Energy (DOE) funds:   to maintain more than 1,000 deployed strategic warheads, as counted under the New START Treaty;   to make the F-35 Joint Strike Fighter aircraft capable of carrying nuclear weapons;  for extending the life of tactical versions of the B61 gravity bomb;  for the RDT&amp;E or procurement of a new air-launched cruise missile or for the W80 warhead life extension program;  for the RDT&amp;E or procurement of the ground-based strategic deterrent or any new intercontinental ballistic missile;  for the IW-1 life extension program;  for the Mixed Oxide Fuel Fabrication Facility project at the Savannah River Site, Aiken, South Carolina; or  for the Uranium Processing Facility located at the Y-12 National Security Complex, Oak Ridge, Tennessee.  DOD and DOE must report to Congress on the plans for, and the estimated cost savings from, carrying out this bill.
[EX A]: Smarter Approach to Nuclear Expenditures Act

[EX Q]: Renewable Energy Expansion Act of 2010 - Amends the Internal Revenue Code to: (1) allow taxpayers an election to receive a direct payment for investing in or producing specified energy property in lieu of existing energy tax credits; and (2) extend eligibility for such payments until January 1, 2013.
[EX A]:
To amend the Internal Revenue Code of 1986 to provide an elective payment for specified energy property.